Infliximab
Based on 27 publication(s) in Google Scholar
Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF-α. Infliximab prevents the interaction of TNF-α with TNF-α receptor (TNFR1 and TNFR2). Infliximab has the potential for autoimmune, chronic inflammatory diseases and diabetic neuropathy research.
The component ratio of this product is Active ingredient : Excipients = 9 : 47.
For research use only. We do not sell to patients.
- Purity: 90.3%
- CAS No.: 170277-31-3
- Molecular Weight:145.98 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Infliximab
More- Signal Transduct Target Ther. 2024 Oct 16;9(1):273. [Abstract]
- Adv Mater. 2024 Dec 6:e2412429. [Abstract]
- Bioact Mater. 2025 Nov 28:57:754-767. [Abstract]
- Adv Funct Mater. 2025 Dec 18.
- Adv Sci (Weinh). 2025 Oct 28:e16569. [Abstract]
- Chem Eng J. 2025 Sep 3;522:168039.
- Cancer Lett. 2024 Apr 1:586:216642. [Abstract]
- Int J Biol Sci. 2025 Aug 11;21(12):5206-5222. [Abstract]
- Brain Behav Immun. 2025 May 8:128:620-633. [Abstract]
- Cell Death Discov. 2023 Aug 10;9(1):293. [Abstract]
- NPJ Regen Med. 2023 May 2;8(1):23. [Abstract]
- Acta Neuropathol Commun. 2023 Aug 21;11(1):135. [Abstract]
- mBio. 2024 Jun 3:e0119124. [Abstract]
- Eur J Pharmacol. 2024 Jul 5:974:176611. [Abstract]
- Int Immunopharmacol. 2023 May:118:109976. [Abstract]
- Arthritis Res Ther. 2025 Sep 26;27(1):180. [Abstract]
- Mol Pharm. 2022 Oct 3;19(10):3632-3639. [Abstract]
- Exp Neurol. 2025 Jun:388:115214. [Abstract]
- J Inflamm Res. 2025 Dec 30:18:18205-18228. [Abstract]
- J Inflamm Res. 2025 Feb 19:18:2447-2464. [Abstract]
- Heliyon. 2024 Jun 14;10(12):e33146. [Abstract]
- World J Stem Cells. 2022 Nov 26;14(11):798-814. [Abstract]
- Food Chem Toxicol. 2024 Aug 26:114948. [Abstract]
- Mol Immunol. 2026 Apr:192:1-12. [Abstract]
- Electrophoresis. 2026 Mar 24. [Abstract]
- Electrophoresis. 2025 Sep 23. [Abstract]
- bioRxiv. 2025 Sep 12.
Customer Validation & Images
-
In Vivo Efficacy Study
-
In Vivo Imaging
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
In Vivo Efficacy Study
Biological Activity
The component ratio of this product is Active ingredient : Excipients = 9 : 47.
Human IgG1 kappa
Human
TNFSF2/TNFa
TNF-α-treated adipocytes shows a significant 64% decrease in insulin-stimulated glucose uptake, whereas Infliximab (10 ng/mL) reverses TNF-α actions by significantly improving glucose incorporation in 3T3L1 adipocytes. Infliximab restores phosphorylation of substrate-2 and AKT by attenuating protein-tyrosine phosphatase 1B (PTP1B) activation. Infliximab ameliorates TNF-α-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1.5X106 RAW264.7 cells treated with 1µg/mL LPS for 24h with Infliximab (HY-P9970, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃, Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control，cells without incubation with primary antibody were used as the unlabeled control (black). -
Loaded Infliximab on AHC2 biosensor, can bind TNF-alpha/TNFSF2 Protein, Human (HEK293, His-Avi, HY-P70527) with an affinity constant of <1.000E-11 M as determined in BLI assay.
Chemical Information
-
CAS No. 170277-31-3
-
Appearance Solid
-
Molecular Weight 145.98 kDa
-
Color White to off-white
-
SMILES
[Infliximab]
-
Synonyms
Avakine; CT-P13; SB2; TA-650
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (27)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Cardiomyocyte-specific knockout of ADAM17 alleviates doxorubicin-induced cardiomyopathy via inhibiting TNFα-TRAF3-TAK1-MAPK axis. [Abstract]2024 Oct 16;9(1):273. PMID: 39406701 -
Adv Mater
Probiotics Bi-Enzymatic Cascade Repair System for Editing the Inflammatory Microenvironment to Boost Probiotic Therapy in Inflammatory Bowel Disease. [Abstract]2024 Dec 6:e2412429. PMID: 39641224
Infliximab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Dec 6:e2412429. [Abstract]
Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. Daily change in body weight for each group, including Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Measurements of colonic tissue length in various groups on day 10. DAI changes throughout 10 days, calculated as the total of the stool consistency (0–3), fecal bleeding (0–4), and weight loss (0–4) indexes.
Infliximab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Dec 6:e2412429. [Abstract]
Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. The groups are: Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Mice colonic sections stained with HE on day 10 following the indicated treatments.
Infliximab purchased from MedChemExpress. Usage Cited in: Adv Mater. 2024 Dec 6:e2412429. [Abstract]
Cascade repair probiotic gene editing system improves DSS-induced UC compared with clinical drugs. The groups are: Health, Control, 5-ASA (5-Aminosalicylic acid; 40 mg/kg; oral), vedolizumab (5 mg/kg; iv), ustekinumab (5 mg/kg; iv), infliximab (5 mg/kg; iv), and LGG-M@P, over 10 days. The above drugs were administered once every two days. Colonic MPO levels on day 10.) Colonic TNF-α, IL-6, and IL-1β levels on day 10.
-
Bioact Mater
Hyaluronan regulates the assembly structure and biofunction of polycationic silk fibroin to boost microfracture. [Abstract]2025 Nov 28:57:754-767. PMID: 41403565 -
-
Adv Sci (Weinh)
Repurposing of Chemokine Antagonists for Combined Phase-Resolved Spinal Cord Injury Treatment. [Abstract]2025 Oct 28:e16569. PMID: 41147460
Infliximab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 28:e16569. [Abstract]
38.5 mg/kg infliximab was i.v. administered twice, directly after SCI and 5 days after injury. Representative histoarchitectonics of the spinal cord injured site of SD rats treated with indicated therapeutics in comparison with non-treated SD rats evaluated by Hematoxylin and eosin, Heidenhain’s azan, and anti-GFAP staining were analyzed.
Infliximab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 28:e16569. [Abstract]
38.5 mg/kg infliximab was i.v. administered twice, directly after SCI and 5 days after injury. Representative spinal cord MRI of the injured segment of treated rats was shown in comparison with non-treated SD rats. Hyperintense and hypointense areas were shown by red and blue, respectively.
Infliximab purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2025 Oct 28:e16569. [Abstract]
38.5 mg/kg infliximab was i.v. administered twice, directly after SCI and 5 days after injury. Mean MRI-based semi-quantitative severity score in groups of SD rats treated with the indicated therapeutics was compared with that in non-treated SD rats.
-
-
Cancer Lett
Inhibition of ATM promotes PD-L1 expression by activating JNK/c-Jun/TNF-α signaling axis in triple-negative breast cancer. [Abstract]2024 Apr 1:586:216642. PMID: 38278470 -
Int J Biol Sci
ANXA6 Overexpression Causes Abnormal Decidual Macrophage-Trophoblast Crosstalk in Recurrent Spontaneous Abortion. [Abstract]2025 Aug 11;21(12):5206-5222. PMID: 40959268 -
Brain Behav Immun
Pro-inflammatory macrophages contribute to developing comorbid anxiety-like behaviors through gastrointestinal vagal afferent signaling in experimental colitis mice. [Abstract]2025 May 8:128:620-633. PMID: 40348137 -
Cell Death Discov
Inhibition of Toll-like receptor 4 and Interleukin-1 receptor prevent SARS-CoV-2 mediated kidney injury. [Abstract]2023 Aug 10;9(1):293. PMID: 37563112 -
NPJ Regen Med
Macrophages maintain mammary stem cell activity and mammary homeostasis via TNF-α-PI3K-Cdk1/Cyclin B1 axis. [Abstract]2023 May 2;8(1):23. PMID: 37130846 -
Acta Neuropathol Commun
Inhibition of acid sphingomyelinase reduces reactive astrocyte secretion of mitotoxic extracellular vesicles and improves Alzheimer's disease pathology in the 5xFAD mouse. [Abstract]2023 Aug 21;11(1):135. PMID: 37605262 -
mBio
Human cytomegalovirus UL23 exploits PD-L1 inhibitory signaling pathway to evade T cell-mediated cytotoxicity. [Abstract]2024 Jun 3:e0119124. PMID: 38829126 -
Eur J Pharmacol
Bazedoxifene attenuates dextran sodium sulfate-induced colitis in mice through gut microbiota modulation and inhibition of STAT3 and NF-κB pathways. [Abstract]2024 Jul 5:974:176611. PMID: 38663540 -
Int Immunopharmacol
Melatonin protects against NMDA-induced retinal ganglion cell injury by regulating the microglia-TNFα-RGC p38 MAPK pathway. [Abstract]2023 May:118:109976. PMID: 37098655
Infliximab purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 May:118:109976. [Abstract]
Infliximab (IFX; 10 mg/kg; i.p.; single) significantly increases the number of RGCs in mice.
Infliximab purchased from MedChemExpress. Usage Cited in: Int Immunopharmacol. 2023 May:118:109976. [Abstract]
Infliximab (IFX; 10 mg/kg; i.p.; single) decreases the p-p38/p38 level in NMDA-induced RGC injury mouse retinas.
-
Arthritis Res Ther
2025 Sep 26;27(1):180. PMID: 41013704 -
Mol Pharm
2022 Oct 3;19(10):3632-3639. PMID: 36039398 -
Exp Neurol
2025 Jun:388:115214. PMID: 40068797 -
J Inflamm Res
Exploring the Potential Value of Lactylation and Macrophage Polarization-Related Genes as Biomarkers for TNF-α Inhibitor Response in Inflammatory Bowel Disease. [Abstract]2025 Dec 30:18:18205-18228. PMID: 41497534 -
J Inflamm Res
Cigarette Smoking Induces Skeletal Muscle Atrophy in Mice by Activated Macrophage-Mediated Pyroptosis. [Abstract]2025 Feb 19:18:2447-2464. PMID: 39991657 -
Heliyon
Infliximab inhibits TNF-α-dependent activation of the NLRP3/IL-1β pathway in acne inversa. [Abstract]2024 Jun 14;10(12):e33146. PMID: 38994066 -
World J Stem Cells
Tumor necrosis factor-α inhibition restores matrix formation by human adipose-derived stem cells in the late stage of chondrogenic differentiation. [Abstract]2022 Nov 26;14(11):798-814. PMID: 36483847 -
Food Chem Toxicol
ZnO nanoparticles induce melanoma-like lesions via recruiting dermal dendritic cells in barrier-damaged skin in mice. [Abstract]2024 Aug 26:114948. PMID: 39197528 -
Mol Immunol
Adenovirus induces pediatric pneumonia via triggering macrophage polarization and IL-6 production via NF-κB activation. [Abstract]2026 Apr:192:1-12. PMID: 41762478 -
Electrophoresis
A Separation Buffers Platform Set to Facilitate CZE Charge Heterogeneity Method Development for Monoclonal Antibodies. [Abstract]2026 Mar 24. PMID: 41873887 -
Electrophoresis
Towards an Analytical Procedure Control Strategy for the Capillary Zone Electrophoresis Method for Monoclonal Antibodies: Alternatives for ε-Aminocaproic Acid and Triethylenetetramine. [Abstract]2025 Sep 23. PMID: 40988426 -
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Lucia A Méndez-García, et al. Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro. Scand J Immunol. 2018 Nov;88(5):e12716. [Content Brief]
[2]. Isamu Yamakawa, et al. Inactivation of TNF-α ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz